Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Britain Courts Anthropic Amid US Defense Department Dispute 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
| Nicox to present at the 2017 BIO International Convention June 15, 2017 Sophia Antipolis, France Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that Emmet Purtill, Director Business Development, will present at the 2017 BIO International Convention on Thursday June 22 , 2017 at 11:15 a.m. Pacific Time. The conference is being held at the Convention Center in San Diego. The presentation will be available on Nicox website (www.nicox.com) in "Presentations & Events". Mr. Purtill will also be available for one-on-one meetings at the conference. | |
| About Nicox | |
| Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has an approved NDA product and another product at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com . | |
| Analyst coverage | |
| Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France Stifel Christian Glennie London, UK | |
| Upcoming financial and business conferences | |
| September 25-27 Cantor Fitzgerald's 3rd Annual Healthcare Conference New York; US | |
| Contacts | |
| Nicox Gavin Spencer, Executive Vice President Corporate Development T +33 (0)4 97 24 53 00 [email protected] | |
| Investor Relations Europe NewCap Julien Perez, Valentine Brouchot T +33 (0)1 44 71 94 94 [email protected] | Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 [email protected] |
| United States Argot Partners Melissa Forst T +1 (212) 600-1902 [email protected] | France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 [email protected] |
| United States Argot Partners Eliza Schleifstein T +1 (917) 763-8106 [email protected] | |
| Disclaimer | |
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. | |
| Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 | |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/6169f64c-7da4-49ca-903d-3c77e19bfcb5
